Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Bayer stresses drugs...

    Bayer stresses drugs tolerability in bid for prostate cancer market

    GarimaWritten by Garima Published On 2019-02-17T09:05:57+05:30  |  Updated On 17 Feb 2019 9:05 AM IST
    Bayer stresses drugs tolerability in bid for prostate cancer market

    Bayer is in discussions with regulators about a request for marketing approval and estimates annual peak sales of at least 1 billion euros ($1.13 billion).


    FRANKFURT: Bayer is banking on the mild side effects of its experimental prostate cancer drug darolutamide, as it prepares to take on established rival products by Pfizer and Johnson & Johnson.


    The drug, tested on early-stage prostate cancer that does not respond to hormonal therapy, was shown to be safe to use with only fatigue as the most serious side effect, Bayer said on Thursday, citing a phase-three study that could be decisive for regulatory approval.


    Read Also: Takeda to pay Bayer $155 million over haemophilia drug


    Given the cancer is not yet spreading and patients are still relatively unburdened by the disease, a drug's tolerability is a key concern for the generally elderly men taking it, said Robert LaCaze, Bayer's head of oncology.


    "Patients may be on this drug for two to three, maybe four years ... it really does fit this patient population, we feel, much better than maybe some of the alternatives available today," he said.


    Some initial results of the phase three trial were released earlier this week and sparked disappointment. Shares in Finland's Orion, which sold certain rights to the drug in a collaboration deal with Bayer in 2014, fell as a result.


    The details showed darolutamide held off metastases for nearly two years when compared to placebo but analysts doubted this would give darolutamide an edge over approved drugs Xtandi by Astellas and Pfizer as well as J&J's Erleada.


    Bayer is in discussions with regulators about a request for marketing approval and estimates annual peak sales of at least 1 billion euros ($1.13 billion).


    Read Also: Loxo, Bayer gets U.S approval for cancer drug Larotrectinib


    Analysts at UBS and Jefferies said the side effect profile was favourable but questioned whether that would suffice to set the drug apart from its established rivals because efficacy data was roughly on par.


    Full details on the darolutamide study are being presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium on Thursday.


    An ongoing trial comparing Xtandi directly with darolutamide, with patients first taking one and then the other, may provide more clarity in about three years.


    Among the 160,000 new cases of prostate cancer diagnosed per year in the United States roughly 15,000 fall under the category that was tested in the trial, LaCaze said.


    Darolutamide is also being tested on advanced prostate cancer with metastases, a potentially bigger market.


    Bayer is under pressure to strengthen its drug development pipeline as its pharmaceuticals division faces falling sales from 2024 amid likely competition for its two bestselling drugs.


    Read Also: Bayer shares fall 10 pct after Monsanto’s Roundup cancer trial


    Shares in the German company, which acquired seed maker Monsanto, have fallen amid U.S. lawsuits claiming its Roundup weed-killer played a role in the plaintiffs' cancer.

    American Society of Clinical Oncology Genitourinary Cancers SymposiumAstellas PharmaBayercancer drug darolutamideCollaborationdrugs tolerabilitydrugs XtandiFrankfurthead of oncologyhormonal therapyJohnson & JohnsonmetastasesoncologyPfizerplaintiffs cancerprostate cancerRobert LaCazeUnited States
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Garima
    Garima

      Garima joined Medical Dialogues in the year 2017 and is currently working as a Senior Editor. She looks after all the Healthcare news pertaining to Medico-legal cases, MCI/DCI decisions, Medical Education issues, government policies as well as all the news and updates concerning Medical and Dental Colleges in India. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok